These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 36604351

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N, Flanagan L, Harford J, Gannon JM, Quinn CM.
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [Abstract] [Full Text] [Related]

  • 3. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY.
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [Abstract] [Full Text] [Related]

  • 4. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
    Prendeville S, Feeley L, Bennett MW, O'Connell F, Browne TJ.
    Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
    [Abstract] [Full Text] [Related]

  • 5. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
    Farshid G, Dhatrak D, Gilhotra A, Koszyca B, Nolan J.
    Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
    [Abstract] [Full Text] [Related]

  • 6. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH, Wang K, Lin DY, Xu J, Chen J, Long XY, Ge Y, Luo XL, Zhang KP, Liu YH, Xu FP.
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [Abstract] [Full Text] [Related]

  • 7. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B, Ding W, Sun K, Wang X, Xu L, Teng X.
    Sci Rep; 2019 Nov 13; 9(1):16726. PubMed ID: 31723206
    [Abstract] [Full Text] [Related]

  • 8. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
    Hanna WM, Barnes PJ, Chang MC, Gilks CB, Magliocco AM, Rees H, Quenneville L, Robertson SJ, SenGupta SK, Nofech-Mozes S.
    J Clin Oncol; 2014 Dec 10; 32(35):3967-73. PubMed ID: 25385731
    [Abstract] [Full Text] [Related]

  • 9. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
    Solomon JP, Dell'Aquila M, Fadare O, Hasteh F.
    Am J Clin Pathol; 2017 Apr 01; 147(4):432-437. PubMed ID: 28340220
    [Abstract] [Full Text] [Related]

  • 10. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC, Pettit AS, Veldhuijzen van Zanten D, Barnes PJ.
    Histopathology; 2017 May 01; 70(6):966-974. PubMed ID: 28032917
    [Abstract] [Full Text] [Related]

  • 11. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Liu Y, Wu S, Shi X, Luo Y, Pang J, Wang C, Mao F, Liang Z, Zeng X.
    Breast Cancer Res Treat; 2019 Nov 01; 178(2):275-281. PubMed ID: 31388934
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic Accuracy of Immunohistochemistry for HER2-Positive Breast Cancer.
    Thanasan S, Sukhakul K, Chitpakdee S, Kitkumthorn N.
    Asian Pac J Cancer Prev; 2023 Dec 01; 24(12):4321-4327. PubMed ID: 38156869
    [Abstract] [Full Text] [Related]

  • 13. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists.
    Arch Pathol Lab Med; 2014 Feb 01; 138(2):241-56. PubMed ID: 24099077
    [Abstract] [Full Text] [Related]

  • 14. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
    Curado M, Caramelo AS, Eloy C, Polónia A.
    Virchows Arch; 2019 Sep 01; 475(3):303-311. PubMed ID: 30953146
    [Abstract] [Full Text] [Related]

  • 15. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
    Lim TH, Lim AST, Tien SL, Tan PH.
    Ann Diagn Pathol; 2022 Jun 01; 58():151935. PubMed ID: 35313158
    [Abstract] [Full Text] [Related]

  • 16. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM, de Munck L, de Graaf JC, Siesling S, de Vries EG, Boers JE.
    Eur J Cancer; 2014 Mar 01; 50(5):885-91. PubMed ID: 24491395
    [Abstract] [Full Text] [Related]

  • 17. UK recommendations for HER2 assessment in breast cancer: an update.
    Rakha EA, Tan PH, Quinn C, Provenzano E, Shaaban AM, Deb R, Callagy G, Starczynski J, Lee AHS, Ellis IO, Pinder SE.
    J Clin Pathol; 2023 Apr 01; 76(4):217-227. PubMed ID: 36564170
    [Abstract] [Full Text] [Related]

  • 18. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G, Farrajota P, Olsson A, Silva C, Hartman J, Elmberger G.
    Ann Diagn Pathol; 2015 Aug 01; 19(4):203-10. PubMed ID: 25921313
    [Abstract] [Full Text] [Related]

  • 19. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpatt OF, Gomez C, Zhao W, Reis IM.
    Breast Cancer Res Treat; 2016 Feb 01; 155(3):457-62. PubMed ID: 26895325
    [Abstract] [Full Text] [Related]

  • 20. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z, Noske A.
    PLoS One; 2015 Feb 01; 10(10):e0140652. PubMed ID: 26473483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.